203 results on '"Abrial, C."'
Search Results
2. 20P Spatial analysis of residual tumor tissue provides new clues for post-neoadjuvant treatment approaches in triple-negative breast cancer
3. Place de la tomosynthèse dans le bilan d’extension locorégional d’une néoplasie mammaire chez 75 patientes
4. The role of tomosynthesis in breast cancer staging in 75 patients
5. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
6. Les récepteurs du goût dans le poumon : intéressants ou anecdotiques ?
7. Late lines of treatment benefit survival in metastatic breast cancer in current practice?
8. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
9. 15-Lipoxygenases regulate the production of chemokines in human lung macrophages
10. 326P National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study
11. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
12. Intraoperative Imprint Cytology Examination of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy in Breast Cancer Patients
13. Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors
14. Clinicopathological Factors and Nomograms Predicting Nonsentinel Lymph Node Metastases After Neoadjuvant Chemotherapy in Breast Cancer Patients
15. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation
16. Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers
17. Indications, contre–indications, résultats attendus et choix de la chimiothérapie néo–adjuvante du cancer du sein opérable
18. Neoadjuvant endocrine therapy in breast cancer
19. Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists
20. Abstract P5-12-09: The ≥5% cut-off reveals tumor PD-L1 positivity as potential selection biomarker for patient enrollment into the trials evaluating anti-PD-1 or anti-PD-L1 agents in neoadjuvant treatment of triple negative breast cancer
21. Caractérisation de l’expression et du rôle des récepteurs à l’amertume dans les macrophages pulmonaires humains
22. Abstract P2-09-29: Potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy, revealed by genomic analyses and assessment of tumor-infiltrating lymphocytes
23. Abstract P4-15-03: Tumor-infiltrating lymphocytes in breast ductal carcinoma in situ: Correlations with tumor pathobiology in a French cohort of 495 cases (BONBIS)
24. Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy
25. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
26. Thymic stromal lymphopoietin induces cytokine production by human lung macrophages
27. LBA12 - Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy
28. Quality of life after mastectomy with or without immediate breast reconstruction.
29. Quand faire de la chimiothérapie néoadjuvante? Ľutilisation de la chimiothérapie néoadjuvante chez des patientes atteintes de cancer du sein opérable (stades II et III)
30. Everolimus Plus Hormonotherapy (Ht) Induces Survival Gain in Late Metastatic Breast Cancer (Mbc) After Progression: Could this Line Be Better Than a Late New Chemotherapy (Ct) Line?
31. Abstract P5-08-07: HER3, MET and immune pathways play important roles in the resistance of triple negative breast cancer (TNBC) after neoadjuvant anti-EGFR (panitumumab) combined with FEC 100
32. Abstract P3-14-19: Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome
33. Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial
34. Abstract P3-06-20: Is it possible to predict the efficacy of a combination of Panitumumab plus FEC 100 followed by docetaxel (T) for patients with triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial.
35. Survie globale (SG) et survie sans rechute (SSR) dans différents sous-groupes de cancers du sein : luminal A, luminal B, triple négatifs et Her2+, traités par chimiothérapie néoadjuvante (CTNA)
36. Sub-localisation cellulaire de la P-cadhérine dans les cancers du sein triple négatifs : un marqueur de la transition épithélio-mésenchymateuse ?
37. Long-Term Overall Survival (OS) and Disease-Free Survival (DFS) According to PCR in Breast Cancers Subtypes: Luminal A and B, Triple Negative and HER2 +, Treated by Neaodjuvant Chemotherapy (NCT)
38. P3-14-01: Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
39. P5-14-20: Neoadjuvant Chemotherapy (NCT) in 466 Patients for Operable Breast Cancer: The Prognostic Value of SBR Grade Variation.
40. Prognostic Value of Initial Tumor Parameters After Metastatic Relapse
41. 5052 POSTER Non Basal Like Phenotype: a Potential Predictive Factor for the Effectiveness of Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
42. 5159 POSTER A Randomized Study Comparing Standard to Response-adapted Sequence in HER2 Negative Operable Breast Cancer
43. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
44. Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC).
45. What is the survival length from the late lines of treatment in metastatic breast cancer?
46. Abstract P1-01-15: Intraoperative Imprint Cytology Examination of Sentinel Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer Patients
47. Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer: Predictive factors for pathological response.
48. Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results.
49. Sequential FEC 100-Docetaxel (T) Neoadjuvant Chemotherapy (NCT) in Stage II-III Operable Breast Cancer.
50. Weight Variation during Chemotherapy and Breast Cancer Prognostic.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.